Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00238602 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Cancer
A Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00238602: Completed Phase 1 study, sponsored by Stanford University.
NCT00238602 is a Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00238602, a Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study has two primary objectives. The first objective is to determine the maximal tolerated dose (MTD) that can be delivered with stereotactic radiosurgery in patients with inoperable malignant lung tumors. Once the MTD is established, the second objective is to determine the efficacy of radiosurgical ablation of lung tumors in terms of symptoms and radiographic responses.
Interventions
- PROCEDURE Stereotactic radiosurgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2000-03 |
| Est. Completion | 2012-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00238602
The ClinicalTrials.gov registry entry for NCT00238602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stereotactic radiosurgery is the first listed.
NCT00238602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00238602 about?
NCT00238602 is a clinical study titled "Evaluation of Cyberknife Precision Radiation Delivery System for Unresectable Malignant Lung Cancer". This study has two primary objectives. The first objective is to determine the maximal tolerated dose (MTD) that can be delivered with stereotactic radiosurgery in patients with inoperable malignant lung tumors. Once the MTD is established, the second objective is to determine the efficacy of radios...
What is the current status of trial NCT00238602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2000-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00238602?
The interventions under investigation include: Stereotactic radiosurgery (PROCEDURE).
Who is sponsoring clinical trial NCT00238602?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.